难治性咽喉反流病患者更换药物类别的有效性
这项多中心回顾性病例系列结合前瞻性数据,纳入2017年9月至2023年12月治疗的难治性咽喉反流病患者,评估更换药物类别后反流症状评分(RSS)的变化。334份病历中74例(22.2%)为难治性咽喉反流病,更换药物类别与治疗后3至6个月RSS和RSA显著降低相关,但30例(39%)换药后症状未减轻。将藻酸盐换为镁铝加合物、镁铝加合物换为藻酸盐的应答率最高(76.9%)。
要点
- 334份病历中74例(22.2%)为难治性咽喉反流病,定义为治疗前至治疗后3个月RSS无变化。
- 更换药物类别与治疗后3至6个月RSS和RSA显著降低相关,但30例(39%)换药后症状未减轻。
- 藻酸盐与镁铝加合物互换的应答率最高(76.9%),基线RSS可预测3个月和6个月RSS。
核心结论
- 更换药物类别,尤其是将藻酸盐换为镁铝加合物,可能是难治性咽喉反流病患者的有效治疗方法。
研究设计与样本
- 回顾性病例系列结合前瞻性数据,多中心研究,收集2017年9月至2023年12月治疗的难治性咽喉反流病患者数据。
- 334份病历中74例(22.2%)患者为难治性咽喉反流病,定义为治疗前至治疗后3个月RSS无变化。
- 平均年龄52.6±15.5岁。
主要发现
- 更换药物类别与治疗后3至6个月RSS和RSA显著降低相关。
- 30例(39%)患者换药后症状未减轻。
- 将藻酸盐换为镁铝加合物及将镁铝加合物换为藻酸盐的应答率最高(76.9%)。
- 更换PPI和藻酸盐/镁铝加合物分子的应答率为62.5%。
- 初始接受PPI联合藻酸盐或镁铝加合物治疗的患者中,仅更换PPI而不更换藻酸盐/镁铝加合物的应答率为37.5%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the effectiveness of drug class changes in patients with refractory laryngopharyngeal reflux disease (LPRD). STUDY DESIGN: Retrospective case series with prospective data. SETTING: Multicenter study. METHODS: The data of patients treated for a refractory LPRD from September 2017 to December 2023 were collected. The effectiveness of drug class changes was assessed through the reflux symptom score (RSS) change. Signs were evaluated with the Reflux Sign Assessment. The RSS reduction was used to categorize the therapeutic responses as mild (20%-40% RSS reduction), moderate (40.1%-60% RSS reduction), high (60.1%-80%), and complete (>80%). RESULTS: Among the 334 medical records, 74 (22.2%) patients had refractory LPRD defined as no RSS change in the pre- to 3-month posttreatment. The mean age was 52.6 ± 15.5 years. Changing drug class was associated with significant 3- to 6-month posttreatment reductions of RSS and RSA. Thirty patients (39%) did not experience symptom reduction after changing drugs. Changing alginate to magaldrate and magaldrate to alginate was associated with the highest responder rate (76.9%). Changing PPI and alginate/magaldrate molecules led to a response rate of 62.5%. In patients initially treated with a combination of PPI and alginate or magaldrate, changing PPI without changing alginate/magaldrate led to a 37.5% response rate. The baseline RSS was predictive of the 3- and 6-month RSS (therapeutic response). CONCLUSION: Changing drug class, especially alginate-to-magaldrate, may be an effective therapeutic approach for patients with a refractory LPRD.
引用
- Herman E, Saussez S, Lechien JR, et al. Effectiveness of Changing Drug Classes in Patients With Refractory Laryngopharyngeal Reflux Disease. Otolaryngol Head Neck Surg. 2024. PMID: 39350512. doi:10.1002/ohn.996
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。